机构：[1]Department of Clinical Pharmacy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China临床药学部临床药学部四川省人民医院四川省肿瘤医院[2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital and四川大学华西医院
Science and Technology Program of Sichuan Province [2021YFH0145]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82073687]
第一作者机构：[1]Department of Clinical Pharmacy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
通讯作者：
推荐引用方式(GB/T 7714)：
Zhu Y.,Chen X.,Zhang Q.,et al.SKLB-0322, a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer[J].ANNALS OF ONCOLOGY.2022,33:S7-S7.doi:10.1016/j.annonc.2022.01.012.
APA：
Zhu, Y.,Chen, X.,Zhang, Q.,Zeng, J.,Xiao, H.&Yu, L..(2022).SKLB-0322, a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer.ANNALS OF ONCOLOGY,33,
MLA：
Zhu, Y.,et al."SKLB-0322, a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer".ANNALS OF ONCOLOGY 33.(2022):S7-S7
医学